Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARAMOUNT: mRNA-3927 in Propionic Acidemia (Japan)
jRCT2043240044Phase 2Recruiting
- Sponsor
- Moderna Inc
- Start
- Oct 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, open-label trial of mRNA-3927 in propionic acidemia (PA) (2 arms), sponsored by Moderna Inc. Primary endpoints: Change in annualized frequency of CEC-adjudicated metabolic decompensation events (MDEs) and Incidence and severity of TEAEs, SAEs, AESIs, and TEAEs leading to discontinuation. Started Oct 2024; status: recruiting.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on jRCT2043240044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043240044.